综合分子分析识别了泰国和阿拉伯联合长国患有晚期恶性瘤的患者的可操作生物标志物
Shaheenah Dawood1,2, Vasanti Natarajan3, Pongwut Danchaivijitr4
1Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates.
Frontiers in oncology
|May 27, 2024
概括
对先进的固体瘤进行了全面的分子分析,在75%的病例中发现了可采取行动的变化. 这种方法分析DNA,RNA和蛋白质,有助于指导个性化治疗并改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 翻译医学是一种翻译医学.
背景情况:
- 全面的分子分析对于指导癌症治疗至关重要,但缺乏全球可访问性.
- 先进的固体瘤需要精确的治疗策略,以分子数据为基础.
研究的目的:
- 评估在阿联和泰国高级固体瘤患者中综合分子分析的实用性.
- 在多样化的患者群体中识别常见的分子变化和相关的治疗点.
主要方法:
- 从阿联和泰国的晚期癌症患者的451个瘤组织样本进行了回顾性分析.
- 利用了Caris分子智能,分析了DNA (NGS,FISH,火烧测序),RNA (全转录组测序,多重PCR) 和蛋白质 (免疫组织化学).
- 检查了突变,放大,过度表达,拷贝数变化,微卫星不稳定性,缺陷不匹配修复,瘤突变负担和融合.
主要成果:
- 在75%的分析瘤样本中,与相关疗法相关的可操作的分子变化被确定.
- 常见的发现包括PD-L1升高 (可通过免疫检查点抑制剂向) 和HER2放大 (可通过抗HER2疗法向).
- 分析涵盖了35种不同的晚期癌症类型,揭示了不同的分子格局.
结论:
- 对晚期恶性瘤进行全面的分子分析可以优化治疗管理.
- 这种方法促进了个性化治疗策略,可能导致癌症患者的预后结果得到改善.
更多相关视频
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
9.0K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.1K
相关概念视频
Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
